AMENDMENT NO. 1 to PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTProduct Development and Commercialization Agreement • December 20th, 2007 • ChemoCentryx, Inc. • Pharmaceutical preparations
This Amendment No. 1 (“Amendment”) to that certain PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) entered into and made effective as of the 22nd day of August, 2006 by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”), collectively, the “Parties”, is hereby entered into by the Parties with an Amendment effective date of September 30th, 2007 (the “Amendment Effective Date”). All capitalized terms not expressly defined in this Amendment shall have the meanings given to them in the Agreement.
PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN GLAXO GROUP LIMITED and CHEMOCENTRYX, INC.Product Development and Commercialization Agreement • December 20th, 2007 • ChemoCentryx, Inc. • Pharmaceutical preparations • Delaware
This PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into and made effective as of the 22nd day of August, 2006 (the “Effective Date”) by and between ChemoCentryx, Inc., a Delaware corporation having its principal place of business at 850 Maude Avenue, Mountain View, CA 94043 (“ChemoCentryx”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (referred to herein as “GSK”). ChemoCentryx and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
CLINICAL RESEARCH SERVICES AGREEMENTClinical Research Services Agreement • December 20th, 2007 • ChemoCentryx, Inc. • Pharmaceutical preparations
THIS CLINICAL RESEARCH SERVICES AGREEMENT (“Agreement”) made this 12th day of October 2006 (“Effective Date”), by and between CHEMOCENTRYX, INC., a Delaware corporation with its principal executive offices located at 850 Maude Avenue, Mountain View, CA 94043 (“Sponsor”), and KENDLE INTERNATIONAL INC., with its principal executive offices located at 441 Vine Street, 1200 Carew Tower, Cincinnati, OH 45202 (“Kendle”). Kendle and Sponsor may each be referred to individually as a “Party,” and collectively, as “Parties.”
